Development of a Novel Prognostic Marker to Link a Potential Tumor Suppressor Gene at Chromosome 6q to Aberrant Signal Transduction Pathway in Breast Cancer

2005 ◽  
Author(s):  
Pan Zheng
2010 ◽  
Vol 70 (14) ◽  
pp. 6047-6058 ◽  
Author(s):  
Pang-Kuo Lo ◽  
Ji Shin Lee ◽  
Xiaohui Liang ◽  
Liangfeng Han ◽  
Tsuyoshi Mori ◽  
...  

2020 ◽  
Vol 28 ◽  
Author(s):  
Fei Shao ◽  
Xiaonan Pang ◽  
Gyeong Hun Baeg

Abstract:: Breast cancer is the most common malignant tumor in women worldwide. Traditional ways of treatment, includ-ing radiotherapy and endocrine therapy, for breast cancer have inevitable side effects. In recent decades, targeted therapies for breast cancer have rapidly advanced and shown a promising future. The JAK/STAT signaling pathway has been shown to play important roles in tumorigenesis, maintenance and metastasis of breast cancer. Hence, many small molecule inhibi-tors of JAK and STAT proteins have been developed. These inhibitors exhibit potent inhibitory effects on breast cancer in both cellular and animal models, and even some of them have already been in clinical trials. This review article discussed the JAK/STAT signal transduction pathway in the pathogenesis of breast cancer, and the potential for the application of JAK/STAT inhibitors in breast cancer treatment.


PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207776 ◽  
Author(s):  
María del Mar Noblejas-López ◽  
Sara Morcillo-García ◽  
Cristina Nieto-Jiménez ◽  
Miriam Nuncia-Cantarero ◽  
Balázs Győrffy ◽  
...  

Oncogene ◽  
2004 ◽  
Vol 23 (49) ◽  
pp. 8135-8145 ◽  
Author(s):  
Olubunmi Afonja ◽  
Dominique Juste ◽  
Sharmistha Das ◽  
Sachiko Matsuhashi ◽  
Herbert H Samuels

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 223 ◽  
Author(s):  
Begoña Alday-Parejo ◽  
François Richard ◽  
Janine Wörthmüller ◽  
Tilman Rau ◽  
José A. Galván ◽  
...  

Membrane-associated guanylate kinase (MAGUK) with inverted domain structure-1 (MAGI1) is an intracellular adaptor protein that stabilizes epithelial junctions consistent with a tumor suppressive function in several cancers of epithelial origin. Here we report, based on experimental results and human breast cancer (BC) patients’ gene expression data, that MAGI1 is highly expressed and acts as tumor suppressor in estrogen receptor (ER)+/HER2− but not in HER2+ or triple negative breast cancer (TNBC). Within the ER+/HER2− subset, high MAGI1 expression associates with ESR1 and luminal genes GATA3 and FOXA1 expression and better prognosis, while low MAGI1 levels correlates with higher histological grade, more aggressive phenotype and worse prognosis. Experimentally, MAGI1 downregulation in the ER+ human BC cells MCF7 impairs ER expression and signaling, promotes cell proliferation, and reduces apoptosis and epithelial differentiation. MAGI1 downregulation in the ER+ murine BC cell line 67NR accelerates primary tumor growth and enhances experimental lung metastasis formation. MAGI1 expression is upregulated by estrogen/ER, downregulated by prostaglandin E2/COX-2axis, and negatively correlates with inflammation in ER+/HER2− BC patients. Taken together, we show that MAGI1 is a new potential tumor suppressor in ER+/HER2− breast cancer with possible prognostic value for the identification of patients at high-risk of relapse within this subset.


Sign in / Sign up

Export Citation Format

Share Document